Subject: Participation in survey “Letrozole in the context of Ovulation Induction (OI) in infertile women with polycystic ovary syndrome in India”
TInfertility affects approximately one in seven couples in the reproductive age group. Ovulatory dysfunction is diagnosed as a cause of infertility in approximately one-fourth of the infertile couples attending the outpatient clinic.
Polycystic ovary syndrome (PCOS) is the most common ovarian endocrine disease in women of reproductive age, with an incidence among premenopausal women of up to 20% when applying Rotterdam criteria. Oligo-ovulation is the most important and classic clinical manifestation of PCOS, and the resulting infertility is the major cause of anovulatory infertility, which affects many infertile women of reproductive age. Ovulation induction represents the mainstay of treatment for infertile women with PCOS, and is designed to promote growth and maturation of a single dominant follicle with a follow-up singleton pregnancy. Several ovulation induction protocols are available, which have achieved varying success, the main ones being clomiphene citrate, aromatase inhibitors and gonadotrophins, each of which has its own benefits and deficiencies. In recent years, letrozole, a third-generation aromatase inhibitor, has become a first-line treatment for ovulation induction.
There is limited real-world data available on the usage of Letrozole in infertile women with Polycystic Ovary Syndrome (PCOS) in India.
This multicentric survey is designed to understand the usage of Letrozole in infertile women with Polycystic Ovary Syndrome (PCOS) for Ovulation induction.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})